Psychometric evaluation finds varying minimal clinically important differences in depressed patients, indicating greater change is required in treatment-resistant cases.
MCID on the BDI-II is dependent on baseline severity, is best measured on a ratio scale, and the MCID for treatment-resistant depression is larger than that for more typical depression. This has important implications for clinical trials and practice.
No takes yet. Share an insight, caveat, or question.
Button et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: